HIV News and Research

RSS

Two investigational Ebola vaccines well-tolerated in Phase 2 clinical trial

Two investigational vaccines designed to protect against Ebola virus disease were well-tolerated and induced an immune response among 1,000 vaccinated participants in the Phase 2 randomized, placebo-controlled clinical trial called PREVAIL I.

25 Feb 2016

Sangamo presents immunological data from SB-728-T HIV clinical study at CROI 2016

Sangamo BioSciences, Inc., the leader in therapeutic genome editing, announced the presentation of immunological data from the Company's clinical trials of SB-728-T, a ZFP Therapeutic designed to provide functional control of HIV.

25 Feb 2016

Researchers launch clinical trials to test novel cellular-immunotherapy to treat three types of blood cancer

Cancer immunology is based upon boosting the body's own immune system to vanquish malignancies. It is among the fastest growing areas of oncology research. Researchers at UC San Diego Moores Cancer Center have launched three clinical trials to test the safety and efficacy of a novel cellular-immunotherapy that uses modified T cells - one of the immune system's primary weapons - to treat three different types of blood cancer that often defy existing therapies.

24 Feb 2016

New approach to prevent mother to child transmission of HIV

The first findings from a study in the Kingdom of Swaziland on a new approach to reduce mother to child transmission of HIV were presented at the annual Conference on Retroviruses and Opportunistic Infections (CROI 2016) in Boston.

24 Feb 2016

Single dose of zoledronic acid can inhibit bone loss in HIV-infected patients

A single dose of the drug zoledronic acid was found to inhibit the bone loss that is common in HIV-infected patients and that is increased during the first two years of treatment with antiretroviral therapy (ART).

24 Feb 2016

ViiV Healthcare presents positive results from LATTE-2 study at CROI

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today presented positive results from the LATTE-2 study at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. Headline results were announced in November 2015.

24 Feb 2016

ARV drug atazanavir may have significant effects on infant development

The antiretroviral (ARV) drug atazanavir—sometimes included in treatments to prevent mother-to-child HIV transmission during pregnancy—may have small but significant effects on infant development, reports a study in the journal AIDS, official journal of the International AIDS Society.

23 Feb 2016

Dapivirine ring can help prevent HIV-1 infection in women

In an important scientific achievement for women's health, two large Phase III clinical trials -- The Ring Study and ASPIRE -- have shown that a monthly vaginal ring containing the antiretroviral drug (ARV) dapivirine can safely help prevent HIV-1 infection in women.

23 Feb 2016

Researchers develop designer recombinase that can remove provirus from HIV-1 isolates

Researchers at the Medical Faculty of the Technische Universität Dresden and the Heinrich Pette Institute, Leibniz Institute for Experimental Virology succeeded in developing a designer recombinase (Brec1) that is capable of specifically removing the provirus from infected cells of most primary HIV-1 isolates.

23 Feb 2016

Researchers devise new approach to improve current T-cell therapy methods

T-cell therapy, a form of immunotherapy that uses a patient's own immune cells to attack their cancer, has been making waves recently. The "living" therapy involves engineering the patient's T cells in the laboratory to carry new proteins that guide the immune cells directly to tumor cells, allowing the engineered T cells to attack and kill the cancer.

23 Feb 2016

Two Johns Hopkins scientists named among 105 winners of Presidential Early Career Awards

Namandje Bumpus, Ph.D., and Jordan Green, Ph.D., of the Johns Hopkins University School of Medicine are among 105 winners of Presidential Early Career Awards for Scientists and Engineers, which were announced by the White House on Feb. 18.

23 Feb 2016

Study identifies new mechanism for controlling HIV replication

Researchers at University of California, San Diego School of Medicine have discovered that HIV infection of human immune cells triggers a massive increase in methylation, a chemical modification, to both human and viral RNA, aiding replication of the virus.

23 Feb 2016

Researchers identify new group of powerful Ebola-fighting antibodies

A research team that included scientists from The Scripps Research Institute has identified a new group of powerful antibodies to fight Ebola virus.

22 Feb 2016

Mylan announces FDA's acceptance of ANDA filing for generic Advair Diskus

Mylan N.V. today announced that its abbreviated new drug application (ANDA) for fluticasone propionate 100, 250, 500 mcg and salmeterol 50 mcg inhalation powder has been accepted for filing by the U.S. Food and Drug Administration.

22 Feb 2016

Zika virus can cross the placental barrier, according to new study

A study of pregnant women in Brazil has confirmed the presence of Zika virus in the amniotic fluid of two women who had displayed Zika-like symptoms during their pregnancies.

18 Feb 2016

Study demonstrating link between anal cancer and HPV infection published in Obstetrics & Gynecology

Researchers at Women & Infants Hospital, a Care New England hospital, recently published the results of a study demonstrating a connection between anal cancer and human papillomavirus (HPV) infection.

18 Feb 2016

Discovery could lead to more effective vaccines, personalised therapies for TB

Tuberculosis (TB) used to kill one in seven people around the world before the advent of antibiotics. However the increasing prevalence of multi-drug resistant TB means that doctors are running out of options in trying to combat this bacterium.

18 Feb 2016

WRAIR begins Phase 1 clinical trial to evaluate MERS vaccine candidate

The Walter Reed Army Institute of Research began vaccinations today in a Phase 1 clinical trial to evaluate the safety and immune response of a vaccine candidate to prevent Middle East Respiratory Syndrome (MERS).

17 Feb 2016

Transgender people serving in US military report few mental, physical health problems

A new study shows that transgender active-duty U.S. military personnel report few lifetime mental and physical health problems.

17 Feb 2016

Researchers identify how Toxoplasma parasite crosses blood-brain barrier

An estimated 30 percent of the world's population is chronically infected with the parasite Toxoplasma gondii. Most people live with the infection without noticeable effect, but it can be life-threatening for people with suppressed immune systems, such as people on cancer therapies or who have HIV/AIDS.

16 Feb 2016